March, 27th 2013 | Company News:
RiNA GmbH and NeoVentures Biotechnology Inc. jointly announce that they have agreed to enter into a strategic alliance to provide their clients with as full an aptamer discovery, development and commercial production service as possible. This agreement will enable NeoVentures clients to have access to RiNA delivery of spiegelmer based diagnostics, and enable RiNA clients to have access to NeoVentures proprietary positions in the areas of Dubbles selection, sequence analysis, and proprietary diagnostic platforms as well as experience in the commercial delivery of aptamer based diagnostics. Both companies remain committed to displacing antibodies with aptamers as the method of choice for diagnostic platforms. For more information please contact the companies directly at email@example.com or firstname.lastname@example.org.